NasdaqGS:ACLXBiotechs
Assessing Arcellx (ACLX) Valuation After Strong Returns And Fresh Cancer Immunotherapy Data
Arcellx (ACLX) has drawn attention after fresh performance data on its lead cancer immunotherapies prompted investors to reassess both the company’s clinical pipeline and its recent share price strength over the past 3 months.
See our latest analysis for Arcellx.
Over the past year Arcellx’s share price return of 80.88% year to date and 80.14% over 90 days, compared with a 74.65% one year total shareholder return and 290.09% three year total shareholder return, points to strong momentum...